New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
07:59 EDTVCYTVeracyte weakness a buying opportunity, says Cowen
Cowen feels the recent weakness in Veracyte has created a buying opportunity despite the company's lower than expected Q2 revenues and reduced guidance. The firm calls the stock on of its top small-cap picks, citing underlying GEC growth, a strong pipeline, and low valuation. Cowen maintains its Outperform rating and $22 price target on Veracyte.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:32 EDTVCYTVeracyte partners with Pulmonary Fibrosis Foundation on lung disease survey
Veracyte and The Pulmonary Fibrosis Foundation are partnering on a U.S. patient survey to advance understanding of patients' diagnostic experiences with interstitial lung diseases, including idiopathic pulmonary fibrosis. The Interstitial Lung Disease Patient Journey survey will assess the steps and time required for patients to receive a diagnosis, specific obstacles hindering timely diagnosis, and the physical and emotional impact of patients' diagnostic journey.
August 24, 2015
08:29 EDTVCYTWilliam Blair to hold a field trip
Subscribe for More Information
August 17, 2015
07:31 EDTVCYTVeracyte appoints Neil Barth as Chief Medical Officer effective immediately
Veracyte announced the appointment of Neil Barth as Chief Medical Officer, effective immediately. Most recently, he served as chief medical officer for Agendia NV, a molecular diagnostics company focused on oncology, where he guided the company's medical strategic direction, quality initiatives, and interface with regulators and payers.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use